Photo: Reuters
(Reuters) - AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, its chief executive was quoted as saying on Thursday amid questions over the results from its late-stage study.
Instead of adding the trial to an ongoing U.S. process, AstraZeneca might launch a fresh study to evaluate a lower dosage of its vaccine that performed better than a full dosage, Pascal Soriot was quoted as saying in a Bloomberg News report.
The news comes as AstraZeneca faces questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and E.U. regulatory approval.
Several scientists have raised doubts about the robustness of results released on Monday showing the experimental vaccine was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
Soriot said he did not expect the additional trial to delay U.K. and European regulatory approvals.
Original article:
风险提示：本文所述仅代表作者个人观点，不代表 Followme 的官方立场。Followme 不对内容的准确性、完整性或可靠性作出任何保证，对于基于该内容所采取的任何行为，不承担任何责任，除非另有书面明确说明。
暂无评论，立马抢沙发